Esperion Therapeutics | ESPR - Current Assets


Esperion Therapeutics reported $360.46M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 28.54B 722M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Alterity Therapeutics Limited AUD 27.05M 6.16M Jun/2023
Amarin USD 628.33M 21.52M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Cipla INR 249.18B 16.3B Sep/2025
CSL USD 11.85B 542M Jun/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Geron USD 522.34M 16.75M Sep/2025
Grifols EUR 6.28B 92.48M Sep/2025
Halozyme Therapeutics USD 1.33B 206.08M Sep/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 13.02M 2.53M Sep/2025
Moderna USD 6.6B 427M Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025
Vanda Pharmaceuticals USD 367.5M 27.42M Sep/2025